Global Spinal Muscular Atrophy Medicine Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Spinal Muscular Atrophy Medicine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Spinal Muscular Atrophy Medicine Industry Forecast” looks at past sales and reviews total world Spinal Muscular Atrophy Medicine sales in 2024, providing a comprehensive analysis by region and market sector of projected Spinal Muscular Atrophy Medicine sales for 2025 through 2031. With Spinal Muscular Atrophy Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Spinal Muscular Atrophy Medicine industry.
This Insight Report provides a comprehensive analysis of the global Spinal Muscular Atrophy Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Spinal Muscular Atrophy Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Spinal Muscular Atrophy Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Spinal Muscular Atrophy Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Spinal Muscular Atrophy Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Spinal Muscular Atrophy Medicine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Spinal Muscular Atrophy Medicine market?
What factors are driving Spinal Muscular Atrophy Medicine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Spinal Muscular Atrophy Medicine market opportunities vary by end market size?
How does Spinal Muscular Atrophy Medicine break out by Type, by Application?
The global Spinal Muscular Atrophy Medicine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Spinal Muscular Atrophy Medicine Industry Forecast” looks at past sales and reviews total world Spinal Muscular Atrophy Medicine sales in 2024, providing a comprehensive analysis by region and market sector of projected Spinal Muscular Atrophy Medicine sales for 2025 through 2031. With Spinal Muscular Atrophy Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Spinal Muscular Atrophy Medicine industry.
This Insight Report provides a comprehensive analysis of the global Spinal Muscular Atrophy Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Spinal Muscular Atrophy Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Spinal Muscular Atrophy Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Spinal Muscular Atrophy Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Spinal Muscular Atrophy Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Spinal Muscular Atrophy Medicine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- LMI-070
- ND-602
- NT-1654
- Nusinersen
- NXD-30001
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Pharma Inc.
- AveXis, Inc.
- Bioblast Pharma Ltd.
- Cytokinetics, Inc. 24
- F. Hoffmann-La Roche Ltd.
- Genethon
- Genzyme Corporation
- GMP-Orphan SAS
- Ionis Pharmaceuticals, Inc.
- Longevity Biotech, Inc
- Neurodyn Inc.
- Neurotune AG
- Novartis AG
- Sarepta Therapeutics, Inc.
- Voyager Therapeutics, Inc.
- Vybion, Inc.
- WAVE Life Sciences Ltd.
What is the 10-year outlook for the global Spinal Muscular Atrophy Medicine market?
What factors are driving Spinal Muscular Atrophy Medicine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Spinal Muscular Atrophy Medicine market opportunities vary by end market size?
How does Spinal Muscular Atrophy Medicine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Country/Region, 2020, 2024 & 2031
2.2 Spinal Muscular Atrophy Medicine Segment by Type
2.2.1 LMI-070
2.2.2 ND-602
2.2.3 NT-1654
2.2.4 Nusinersen
2.2.5 NXD-30001
2.2.6 Others
2.3 Spinal Muscular Atrophy Medicine Sales by Type
2.3.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
2.3.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Type (2020-2025)
2.4 Spinal Muscular Atrophy Medicine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Spinal Muscular Atrophy Medicine Sales by Application
2.5.1 Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2020-2025)
2.5.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Spinal Muscular Atrophy Medicine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Spinal Muscular Atrophy Medicine Breakdown Data by Company
3.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Company (2020-2025)
3.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2020-2025)
3.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Company (2020-2025)
3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Company (2020-2025)
3.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2020-2025)
3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Company
3.4 Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Spinal Muscular Atrophy Medicine Product Location Distribution
3.4.2 Players Spinal Muscular Atrophy Medicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
4.1 World Historic Spinal Muscular Atrophy Medicine Market Size by Geographic Region (2020-2025)
4.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Spinal Muscular Atrophy Medicine Market Size by Country/Region (2020-2025)
4.2.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Spinal Muscular Atrophy Medicine Sales Growth
4.4 APAC Spinal Muscular Atrophy Medicine Sales Growth
4.5 Europe Spinal Muscular Atrophy Medicine Sales Growth
4.6 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Growth
5 AMERICAS
5.1 Americas Spinal Muscular Atrophy Medicine Sales by Country
5.1.1 Americas Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)
5.1.2 Americas Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)
5.2 Americas Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
5.3 Americas Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Spinal Muscular Atrophy Medicine Sales by Region
6.1.1 APAC Spinal Muscular Atrophy Medicine Sales by Region (2020-2025)
6.1.2 APAC Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025)
6.2 APAC Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
6.3 APAC Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Spinal Muscular Atrophy Medicine by Country
7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)
7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)
7.2 Europe Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
7.3 Europe Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Spinal Muscular Atrophy Medicine by Country
8.1.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)
8.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
8.3 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine
10.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
10.4 Industry Chain Structure of Spinal Muscular Atrophy Medicine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Spinal Muscular Atrophy Medicine Distributors
11.3 Spinal Muscular Atrophy Medicine Customer
12 WORLD FORECAST REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
12.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region
12.1.1 Global Spinal Muscular Atrophy Medicine Forecast by Region (2026-2031)
12.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Spinal Muscular Atrophy Medicine Forecast by Type (2026-2031)
12.7 Global Spinal Muscular Atrophy Medicine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma Inc.
13.1.1 Astellas Pharma Inc. Company Information
13.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Astellas Pharma Inc. Main Business Overview
13.1.5 Astellas Pharma Inc. Latest Developments
13.2 AveXis, Inc.
13.2.1 AveXis, Inc. Company Information
13.2.2 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AveXis, Inc. Main Business Overview
13.2.5 AveXis, Inc. Latest Developments
13.3 Bioblast Pharma Ltd.
13.3.1 Bioblast Pharma Ltd. Company Information
13.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Bioblast Pharma Ltd. Main Business Overview
13.3.5 Bioblast Pharma Ltd. Latest Developments
13.4 Cytokinetics, Inc.
13.4.1 Cytokinetics, Inc. 24 Company Information
13.4.2 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Cytokinetics, Inc. 24 Main Business Overview
13.4.5 Cytokinetics, Inc. 24 Latest Developments
13.5 F. Hoffmann-La Roche Ltd.
13.5.1 F. Hoffmann-La Roche Ltd. Company Information
13.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 F. Hoffmann-La Roche Ltd. Main Business Overview
13.5.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.6 Genethon
13.6.1 Genethon Company Information
13.6.2 Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Genethon Main Business Overview
13.6.5 Genethon Latest Developments
13.7 Genzyme Corporation
13.7.1 Genzyme Corporation Company Information
13.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Genzyme Corporation Main Business Overview
13.7.5 Genzyme Corporation Latest Developments
13.8 GMP-Orphan SAS
13.8.1 GMP-Orphan SAS Company Information
13.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 GMP-Orphan SAS Main Business Overview
13.8.5 GMP-Orphan SAS Latest Developments
13.9 Ionis Pharmaceuticals, Inc.
13.9.1 Ionis Pharmaceuticals, Inc. Company Information
13.9.2 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Ionis Pharmaceuticals, Inc. Main Business Overview
13.9.5 Ionis Pharmaceuticals, Inc. Latest Developments
13.10 Longevity Biotech, Inc
13.10.1 Longevity Biotech, Inc Company Information
13.10.2 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Longevity Biotech, Inc Main Business Overview
13.10.5 Longevity Biotech, Inc Latest Developments
13.11 Neurodyn Inc.
13.11.1 Neurodyn Inc. Company Information
13.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Neurodyn Inc. Main Business Overview
13.11.5 Neurodyn Inc. Latest Developments
13.12 Neurotune AG
13.12.1 Neurotune AG Company Information
13.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Neurotune AG Main Business Overview
13.12.5 Neurotune AG Latest Developments
13.13 Novartis AG
13.13.1 Novartis AG Company Information
13.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Novartis AG Main Business Overview
13.13.5 Novartis AG Latest Developments
13.14 Sarepta Therapeutics, Inc.
13.14.1 Sarepta Therapeutics, Inc. Company Information
13.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Sarepta Therapeutics, Inc. Main Business Overview
13.14.5 Sarepta Therapeutics, Inc. Latest Developments
13.15 Voyager Therapeutics, Inc.
13.15.1 Voyager Therapeutics, Inc. Company Information
13.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Voyager Therapeutics, Inc. Main Business Overview
13.15.5 Voyager Therapeutics, Inc. Latest Developments
13.16 Vybion, Inc.
13.16.1 Vybion, Inc. Company Information
13.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Vybion, Inc. Main Business Overview
13.16.5 Vybion, Inc. Latest Developments
13.17 WAVE Life Sciences Ltd.
13.17.1 WAVE Life Sciences Ltd. Company Information
13.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 WAVE Life Sciences Ltd. Main Business Overview
13.17.5 WAVE Life Sciences Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of LMI-070
Table 4. Major Players of ND-602
Table 5. Major Players of NT-1654
Table 6. Major Players of Nusinersen
Table 7. Major Players of NXD-30001
Table 8. Major Players of Others
Table 9. Global Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 10. Global Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Table 11. Global Spinal Muscular Atrophy Medicine Revenue byType (2020-2025) & ($ million)
Table 12. Global Spinal Muscular Atrophy Medicine Revenue Market Share byType (2020-2025)
Table 13. Global Spinal Muscular Atrophy Medicine Sale Price byType (2020-2025) & (USD/Pcs)
Table 14. Global Spinal Muscular Atrophy Medicine Sale by Application (2020-2025) & (K Pcs)
Table 15. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2020-2025)
Table 16. Global Spinal Muscular Atrophy Medicine Revenue by Application (2020-2025) & ($ million)
Table 17. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2020-2025)
Table 18. Global Spinal Muscular Atrophy Medicine Sale Price by Application (2020-2025) & (USD/Pcs)
Table 19. Global Spinal Muscular Atrophy Medicine Sales by Company (2020-2025) & (K Pcs)
Table 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2020-2025)
Table 21. Global Spinal Muscular Atrophy Medicine Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2020-2025)
Table 23. Global Spinal Muscular Atrophy Medicine Sale Price by Company (2020-2025) & (USD/Pcs)
Table 24. Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution and Sales Area
Table 25. Players Spinal Muscular Atrophy Medicine Products Offered
Table 26. Spinal Muscular Atrophy Medicine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Spinal Muscular Atrophy Medicine Sales by Geographic Region (2020-2025) & (K Pcs)
Table 30. Global Spinal Muscular Atrophy Medicine Sales Market Share Geographic Region (2020-2025)
Table 31. Global Spinal Muscular Atrophy Medicine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Spinal Muscular Atrophy Medicine Sales by Country/Region (2020-2025) & (K Pcs)
Table 34. Global Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2020-2025)
Table 35. Global Spinal Muscular Atrophy Medicine Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 38. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2025)
Table 39. Americas Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 41. Americas Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 42. APAC Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K Pcs)
Table 43. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
Table 44. APAC Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 46. APAC Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 47. Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 48. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 50. Europe Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Spinal Muscular Atrophy Medicine
Table 56. Key Market Challenges & Risks of Spinal Muscular Atrophy Medicine
Table 57. Key IndustryTrends of Spinal Muscular Atrophy Medicine
Table 58. Spinal Muscular Atrophy Medicine Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Spinal Muscular Atrophy Medicine Distributors List
Table 61. Spinal Muscular Atrophy Medicine Customer List
Table 62. Global Spinal Muscular Atrophy Medicine SalesForecast by Region (2026-2031) & (K Pcs)
Table 63. Global Spinal Muscular Atrophy Medicine RevenueForecast by Region (2026-2031) & ($ millions)
Table 64. Americas Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Spinal Muscular Atrophy Medicine Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 66. APAC Spinal Muscular Atrophy Medicine SalesForecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Spinal Muscular Atrophy Medicine Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 68. Europe Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Spinal Muscular Atrophy Medicine RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Spinal Muscular Atrophy Medicine RevenueForecast by Country (2026-2031) & ($ millions)
Table 72. Global Spinal Muscular Atrophy Medicine SalesForecast byType (2026-2031) & (K Pcs)
Table 73. Global Spinal Muscular Atrophy Medicine RevenueForecast byType (2026-2031) & ($ millions)
Table 74. Global Spinal Muscular Atrophy Medicine SalesForecast by Application (2026-2031) & (K Pcs)
Table 75. Global Spinal Muscular Atrophy Medicine RevenueForecast by Application (2026-2031) & ($ millions)
Table 76. Astellas Pharma Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 77. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 78. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 79. Astellas Pharma Inc. Main Business
Table 80. Astellas Pharma Inc. Latest Developments
Table 81. AveXis, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 82. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 83. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 84. AveXis, Inc. Main Business
Table 85. AveXis, Inc. Latest Developments
Table 86. Bioblast Pharma Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 87. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 88. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 89. Bioblast Pharma Ltd. Main Business
Table 90. Bioblast Pharma Ltd. Latest Developments
Table 91. Cytokinetics, Inc. 24 Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 92. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 93. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 94. Cytokinetics, Inc. 24 Main Business
Table 95. Cytokinetics, Inc. 24 Latest Developments
Table 96.F. Hoffmann-La Roche Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 97.F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 98.F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 99.F. Hoffmann-La Roche Ltd. Main Business
Table 100.F. Hoffmann-La Roche Ltd. Latest Developments
Table 101. Genethon Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 102. Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 103. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. Genethon Main Business
Table 105. Genethon Latest Developments
Table 106. Genzyme Corporation Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 107. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 108. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 109. Genzyme Corporation Main Business
Table 110. Genzyme Corporation Latest Developments
Table 111. GMP-Orphan SAS Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 112. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 113. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 114. GMP-Orphan SAS Main Business
Table 115. GMP-Orphan SAS Latest Developments
Table 116. Ionis Pharmaceuticals, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 117. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 118. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 119. Ionis Pharmaceuticals, Inc. Main Business
Table 120. Ionis Pharmaceuticals, Inc. Latest Developments
Table 121. Longevity Biotech, Inc Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 122. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 123. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 124. Longevity Biotech, Inc Main Business
Table 125. Longevity Biotech, Inc Latest Developments
Table 126. Neurodyn Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 127. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 128. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 129. Neurodyn Inc. Main Business
Table 130. Neurodyn Inc. Latest Developments
Table 131. Neurotune AG Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 132. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 133. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 134. Neurotune AG Main Business
Table 135. Neurotune AG Latest Developments
Table 136. Novartis AG Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 137. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 138. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 139. Novartis AG Main Business
Table 140. Novartis AG Latest Developments
Table 141. SareptaTherapeutics, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 142. SareptaTherapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 143. SareptaTherapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 144. SareptaTherapeutics, Inc. Main Business
Table 145. SareptaTherapeutics, Inc. Latest Developments
Table 146. VoyagerTherapeutics, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 147. VoyagerTherapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 148. VoyagerTherapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 149. VoyagerTherapeutics, Inc. Main Business
Table 150. VoyagerTherapeutics, Inc. Latest Developments
Table 151. Vybion, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 152. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 153. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 154. Vybion, Inc. Main Business
Table 155. Vybion, Inc. Latest Developments
Table 156. WAVE Life Sciences Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 157. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 158. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 159. WAVE Life Sciences Ltd. Main Business
Table 160. WAVE Life Sciences Ltd. Latest Developments
LIST OFFIGURES
Figure 1. Picture of Spinal Muscular Atrophy Medicine
Figure 2. Spinal Muscular Atrophy Medicine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Spinal Muscular Atrophy Medicine Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Spinal Muscular Atrophy Medicine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Spinal Muscular Atrophy Medicine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2024)
Figure 10. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of LMI-070
Figure 12. Product Picture of ND-602
Figure 13. Product Picture of NT-1654
Figure 14. Product Picture of Nusinersen
Figure 15. Product Picture of NXD-30001
Figure 16. Product Picture of Others
Figure 17. Global Spinal Muscular Atrophy Medicine Sales Market Share byType in 2025
Figure 18. Global Spinal Muscular Atrophy Medicine Revenue Market Share byType (2020-2025)
Figure 19. Spinal Muscular Atrophy Medicine Consumed in Hospital
Figure 20. Global Spinal Muscular Atrophy Medicine Market: Hospital (2020-2025) & (K Pcs)
Figure 21. Spinal Muscular Atrophy Medicine Consumed in Clinic
Figure 22. Global Spinal Muscular Atrophy Medicine Market: Clinic (2020-2025) & (K Pcs)
Figure 23. Spinal Muscular Atrophy Medicine Consumed in Others
Figure 24. Global Spinal Muscular Atrophy Medicine Market: Others (2020-2025) & (K Pcs)
Figure 25. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2024)
Figure 26. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application in 2025
Figure 27. Spinal Muscular Atrophy Medicine Sales by Company in 2025 (K Pcs)
Figure 28. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company in 2025
Figure 29. Spinal Muscular Atrophy Medicine Revenue by Company in 2025 ($ millions)
Figure 30. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company in 2025
Figure 31. Global Spinal Muscular Atrophy Medicine Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 34. Americas Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 35. APAC Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 36. APAC Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 37. Europe Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 38. Europe Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 40. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 41. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 42. Americas Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)
Figure 43. Americas Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 44. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 45. United States Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2025
Figure 50. APAC Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)
Figure 51. APAC Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 52. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 53. China Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 57. India Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 59. ChinaTaiwan Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 61. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)
Figure 62. Europe Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 63. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 64. Germany Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 65.France Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 71. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 72. Egypt Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 75.Turkey Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2025
Figure 78. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure 79. Industry Chain Structure of Spinal Muscular Atrophy Medicine
Figure 80. Channels of Distribution
Figure 81. Global Spinal Muscular Atrophy Medicine Sales MarketForecast by Region (2026-2031)
Figure 82. Global Spinal Muscular Atrophy Medicine Revenue Market ShareForecast by Region (2026-2031)
Figure 83. Global Spinal Muscular Atrophy Medicine Sales Market ShareForecast byType (2026-2031)
Figure 84. Global Spinal Muscular Atrophy Medicine Revenue Market ShareForecast byType (2026-2031)
Figure 85. Global Spinal Muscular Atrophy Medicine Sales Market ShareForecast by Application (2026-2031)
Figure 86. Global Spinal Muscular Atrophy Medicine Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Country/Region, 2020, 2024 & 2031
2.2 Spinal Muscular Atrophy Medicine Segment by Type
2.2.1 LMI-070
2.2.2 ND-602
2.2.3 NT-1654
2.2.4 Nusinersen
2.2.5 NXD-30001
2.2.6 Others
2.3 Spinal Muscular Atrophy Medicine Sales by Type
2.3.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
2.3.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Type (2020-2025)
2.4 Spinal Muscular Atrophy Medicine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Spinal Muscular Atrophy Medicine Sales by Application
2.5.1 Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2020-2025)
2.5.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Spinal Muscular Atrophy Medicine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Spinal Muscular Atrophy Medicine Breakdown Data by Company
3.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Company (2020-2025)
3.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2020-2025)
3.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Company (2020-2025)
3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Company (2020-2025)
3.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2020-2025)
3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Company
3.4 Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Spinal Muscular Atrophy Medicine Product Location Distribution
3.4.2 Players Spinal Muscular Atrophy Medicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
4.1 World Historic Spinal Muscular Atrophy Medicine Market Size by Geographic Region (2020-2025)
4.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Spinal Muscular Atrophy Medicine Market Size by Country/Region (2020-2025)
4.2.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Spinal Muscular Atrophy Medicine Sales Growth
4.4 APAC Spinal Muscular Atrophy Medicine Sales Growth
4.5 Europe Spinal Muscular Atrophy Medicine Sales Growth
4.6 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Growth
5 AMERICAS
5.1 Americas Spinal Muscular Atrophy Medicine Sales by Country
5.1.1 Americas Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)
5.1.2 Americas Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)
5.2 Americas Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
5.3 Americas Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Spinal Muscular Atrophy Medicine Sales by Region
6.1.1 APAC Spinal Muscular Atrophy Medicine Sales by Region (2020-2025)
6.1.2 APAC Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025)
6.2 APAC Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
6.3 APAC Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Spinal Muscular Atrophy Medicine by Country
7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)
7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)
7.2 Europe Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
7.3 Europe Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Spinal Muscular Atrophy Medicine by Country
8.1.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)
8.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)
8.3 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine
10.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
10.4 Industry Chain Structure of Spinal Muscular Atrophy Medicine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Spinal Muscular Atrophy Medicine Distributors
11.3 Spinal Muscular Atrophy Medicine Customer
12 WORLD FORECAST REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION
12.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region
12.1.1 Global Spinal Muscular Atrophy Medicine Forecast by Region (2026-2031)
12.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Spinal Muscular Atrophy Medicine Forecast by Type (2026-2031)
12.7 Global Spinal Muscular Atrophy Medicine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma Inc.
13.1.1 Astellas Pharma Inc. Company Information
13.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Astellas Pharma Inc. Main Business Overview
13.1.5 Astellas Pharma Inc. Latest Developments
13.2 AveXis, Inc.
13.2.1 AveXis, Inc. Company Information
13.2.2 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AveXis, Inc. Main Business Overview
13.2.5 AveXis, Inc. Latest Developments
13.3 Bioblast Pharma Ltd.
13.3.1 Bioblast Pharma Ltd. Company Information
13.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Bioblast Pharma Ltd. Main Business Overview
13.3.5 Bioblast Pharma Ltd. Latest Developments
13.4 Cytokinetics, Inc.
13.4.1 Cytokinetics, Inc. 24 Company Information
13.4.2 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Cytokinetics, Inc. 24 Main Business Overview
13.4.5 Cytokinetics, Inc. 24 Latest Developments
13.5 F. Hoffmann-La Roche Ltd.
13.5.1 F. Hoffmann-La Roche Ltd. Company Information
13.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 F. Hoffmann-La Roche Ltd. Main Business Overview
13.5.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.6 Genethon
13.6.1 Genethon Company Information
13.6.2 Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Genethon Main Business Overview
13.6.5 Genethon Latest Developments
13.7 Genzyme Corporation
13.7.1 Genzyme Corporation Company Information
13.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Genzyme Corporation Main Business Overview
13.7.5 Genzyme Corporation Latest Developments
13.8 GMP-Orphan SAS
13.8.1 GMP-Orphan SAS Company Information
13.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 GMP-Orphan SAS Main Business Overview
13.8.5 GMP-Orphan SAS Latest Developments
13.9 Ionis Pharmaceuticals, Inc.
13.9.1 Ionis Pharmaceuticals, Inc. Company Information
13.9.2 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Ionis Pharmaceuticals, Inc. Main Business Overview
13.9.5 Ionis Pharmaceuticals, Inc. Latest Developments
13.10 Longevity Biotech, Inc
13.10.1 Longevity Biotech, Inc Company Information
13.10.2 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Longevity Biotech, Inc Main Business Overview
13.10.5 Longevity Biotech, Inc Latest Developments
13.11 Neurodyn Inc.
13.11.1 Neurodyn Inc. Company Information
13.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Neurodyn Inc. Main Business Overview
13.11.5 Neurodyn Inc. Latest Developments
13.12 Neurotune AG
13.12.1 Neurotune AG Company Information
13.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Neurotune AG Main Business Overview
13.12.5 Neurotune AG Latest Developments
13.13 Novartis AG
13.13.1 Novartis AG Company Information
13.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Novartis AG Main Business Overview
13.13.5 Novartis AG Latest Developments
13.14 Sarepta Therapeutics, Inc.
13.14.1 Sarepta Therapeutics, Inc. Company Information
13.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Sarepta Therapeutics, Inc. Main Business Overview
13.14.5 Sarepta Therapeutics, Inc. Latest Developments
13.15 Voyager Therapeutics, Inc.
13.15.1 Voyager Therapeutics, Inc. Company Information
13.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Voyager Therapeutics, Inc. Main Business Overview
13.15.5 Voyager Therapeutics, Inc. Latest Developments
13.16 Vybion, Inc.
13.16.1 Vybion, Inc. Company Information
13.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Vybion, Inc. Main Business Overview
13.16.5 Vybion, Inc. Latest Developments
13.17 WAVE Life Sciences Ltd.
13.17.1 WAVE Life Sciences Ltd. Company Information
13.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
13.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 WAVE Life Sciences Ltd. Main Business Overview
13.17.5 WAVE Life Sciences Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of LMI-070
Table 4. Major Players of ND-602
Table 5. Major Players of NT-1654
Table 6. Major Players of Nusinersen
Table 7. Major Players of NXD-30001
Table 8. Major Players of Others
Table 9. Global Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 10. Global Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Table 11. Global Spinal Muscular Atrophy Medicine Revenue byType (2020-2025) & ($ million)
Table 12. Global Spinal Muscular Atrophy Medicine Revenue Market Share byType (2020-2025)
Table 13. Global Spinal Muscular Atrophy Medicine Sale Price byType (2020-2025) & (USD/Pcs)
Table 14. Global Spinal Muscular Atrophy Medicine Sale by Application (2020-2025) & (K Pcs)
Table 15. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2020-2025)
Table 16. Global Spinal Muscular Atrophy Medicine Revenue by Application (2020-2025) & ($ million)
Table 17. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2020-2025)
Table 18. Global Spinal Muscular Atrophy Medicine Sale Price by Application (2020-2025) & (USD/Pcs)
Table 19. Global Spinal Muscular Atrophy Medicine Sales by Company (2020-2025) & (K Pcs)
Table 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2020-2025)
Table 21. Global Spinal Muscular Atrophy Medicine Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2020-2025)
Table 23. Global Spinal Muscular Atrophy Medicine Sale Price by Company (2020-2025) & (USD/Pcs)
Table 24. Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution and Sales Area
Table 25. Players Spinal Muscular Atrophy Medicine Products Offered
Table 26. Spinal Muscular Atrophy Medicine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Spinal Muscular Atrophy Medicine Sales by Geographic Region (2020-2025) & (K Pcs)
Table 30. Global Spinal Muscular Atrophy Medicine Sales Market Share Geographic Region (2020-2025)
Table 31. Global Spinal Muscular Atrophy Medicine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Spinal Muscular Atrophy Medicine Sales by Country/Region (2020-2025) & (K Pcs)
Table 34. Global Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2020-2025)
Table 35. Global Spinal Muscular Atrophy Medicine Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 38. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2025)
Table 39. Americas Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 41. Americas Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 42. APAC Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K Pcs)
Table 43. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
Table 44. APAC Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 46. APAC Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 47. Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 48. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 50. Europe Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Spinal Muscular Atrophy Medicine
Table 56. Key Market Challenges & Risks of Spinal Muscular Atrophy Medicine
Table 57. Key IndustryTrends of Spinal Muscular Atrophy Medicine
Table 58. Spinal Muscular Atrophy Medicine Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Spinal Muscular Atrophy Medicine Distributors List
Table 61. Spinal Muscular Atrophy Medicine Customer List
Table 62. Global Spinal Muscular Atrophy Medicine SalesForecast by Region (2026-2031) & (K Pcs)
Table 63. Global Spinal Muscular Atrophy Medicine RevenueForecast by Region (2026-2031) & ($ millions)
Table 64. Americas Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Spinal Muscular Atrophy Medicine Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 66. APAC Spinal Muscular Atrophy Medicine SalesForecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Spinal Muscular Atrophy Medicine Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 68. Europe Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Spinal Muscular Atrophy Medicine RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Spinal Muscular Atrophy Medicine RevenueForecast by Country (2026-2031) & ($ millions)
Table 72. Global Spinal Muscular Atrophy Medicine SalesForecast byType (2026-2031) & (K Pcs)
Table 73. Global Spinal Muscular Atrophy Medicine RevenueForecast byType (2026-2031) & ($ millions)
Table 74. Global Spinal Muscular Atrophy Medicine SalesForecast by Application (2026-2031) & (K Pcs)
Table 75. Global Spinal Muscular Atrophy Medicine RevenueForecast by Application (2026-2031) & ($ millions)
Table 76. Astellas Pharma Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 77. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 78. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 79. Astellas Pharma Inc. Main Business
Table 80. Astellas Pharma Inc. Latest Developments
Table 81. AveXis, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 82. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 83. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 84. AveXis, Inc. Main Business
Table 85. AveXis, Inc. Latest Developments
Table 86. Bioblast Pharma Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 87. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 88. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 89. Bioblast Pharma Ltd. Main Business
Table 90. Bioblast Pharma Ltd. Latest Developments
Table 91. Cytokinetics, Inc. 24 Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 92. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 93. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 94. Cytokinetics, Inc. 24 Main Business
Table 95. Cytokinetics, Inc. 24 Latest Developments
Table 96.F. Hoffmann-La Roche Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 97.F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 98.F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 99.F. Hoffmann-La Roche Ltd. Main Business
Table 100.F. Hoffmann-La Roche Ltd. Latest Developments
Table 101. Genethon Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 102. Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 103. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. Genethon Main Business
Table 105. Genethon Latest Developments
Table 106. Genzyme Corporation Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 107. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 108. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 109. Genzyme Corporation Main Business
Table 110. Genzyme Corporation Latest Developments
Table 111. GMP-Orphan SAS Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 112. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 113. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 114. GMP-Orphan SAS Main Business
Table 115. GMP-Orphan SAS Latest Developments
Table 116. Ionis Pharmaceuticals, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 117. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 118. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 119. Ionis Pharmaceuticals, Inc. Main Business
Table 120. Ionis Pharmaceuticals, Inc. Latest Developments
Table 121. Longevity Biotech, Inc Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 122. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 123. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 124. Longevity Biotech, Inc Main Business
Table 125. Longevity Biotech, Inc Latest Developments
Table 126. Neurodyn Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 127. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 128. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 129. Neurodyn Inc. Main Business
Table 130. Neurodyn Inc. Latest Developments
Table 131. Neurotune AG Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 132. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 133. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 134. Neurotune AG Main Business
Table 135. Neurotune AG Latest Developments
Table 136. Novartis AG Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 137. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 138. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 139. Novartis AG Main Business
Table 140. Novartis AG Latest Developments
Table 141. SareptaTherapeutics, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 142. SareptaTherapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 143. SareptaTherapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 144. SareptaTherapeutics, Inc. Main Business
Table 145. SareptaTherapeutics, Inc. Latest Developments
Table 146. VoyagerTherapeutics, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 147. VoyagerTherapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 148. VoyagerTherapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 149. VoyagerTherapeutics, Inc. Main Business
Table 150. VoyagerTherapeutics, Inc. Latest Developments
Table 151. Vybion, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 152. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 153. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 154. Vybion, Inc. Main Business
Table 155. Vybion, Inc. Latest Developments
Table 156. WAVE Life Sciences Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 157. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 158. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 159. WAVE Life Sciences Ltd. Main Business
Table 160. WAVE Life Sciences Ltd. Latest Developments
LIST OFFIGURES
Figure 1. Picture of Spinal Muscular Atrophy Medicine
Figure 2. Spinal Muscular Atrophy Medicine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Spinal Muscular Atrophy Medicine Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Spinal Muscular Atrophy Medicine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Spinal Muscular Atrophy Medicine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2024)
Figure 10. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of LMI-070
Figure 12. Product Picture of ND-602
Figure 13. Product Picture of NT-1654
Figure 14. Product Picture of Nusinersen
Figure 15. Product Picture of NXD-30001
Figure 16. Product Picture of Others
Figure 17. Global Spinal Muscular Atrophy Medicine Sales Market Share byType in 2025
Figure 18. Global Spinal Muscular Atrophy Medicine Revenue Market Share byType (2020-2025)
Figure 19. Spinal Muscular Atrophy Medicine Consumed in Hospital
Figure 20. Global Spinal Muscular Atrophy Medicine Market: Hospital (2020-2025) & (K Pcs)
Figure 21. Spinal Muscular Atrophy Medicine Consumed in Clinic
Figure 22. Global Spinal Muscular Atrophy Medicine Market: Clinic (2020-2025) & (K Pcs)
Figure 23. Spinal Muscular Atrophy Medicine Consumed in Others
Figure 24. Global Spinal Muscular Atrophy Medicine Market: Others (2020-2025) & (K Pcs)
Figure 25. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2024)
Figure 26. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application in 2025
Figure 27. Spinal Muscular Atrophy Medicine Sales by Company in 2025 (K Pcs)
Figure 28. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company in 2025
Figure 29. Spinal Muscular Atrophy Medicine Revenue by Company in 2025 ($ millions)
Figure 30. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company in 2025
Figure 31. Global Spinal Muscular Atrophy Medicine Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 34. Americas Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 35. APAC Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 36. APAC Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 37. Europe Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 38. Europe Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)
Figure 40. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue 2020-2025 ($ millions)
Figure 41. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 42. Americas Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)
Figure 43. Americas Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 44. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 45. United States Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2025
Figure 50. APAC Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)
Figure 51. APAC Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 52. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 53. China Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 57. India Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 59. ChinaTaiwan Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025
Figure 61. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)
Figure 62. Europe Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 63. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 64. Germany Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 65.France Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)
Figure 71. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 72. Egypt Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 75.Turkey Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2025
Figure 78. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure 79. Industry Chain Structure of Spinal Muscular Atrophy Medicine
Figure 80. Channels of Distribution
Figure 81. Global Spinal Muscular Atrophy Medicine Sales MarketForecast by Region (2026-2031)
Figure 82. Global Spinal Muscular Atrophy Medicine Revenue Market ShareForecast by Region (2026-2031)
Figure 83. Global Spinal Muscular Atrophy Medicine Sales Market ShareForecast byType (2026-2031)
Figure 84. Global Spinal Muscular Atrophy Medicine Revenue Market ShareForecast byType (2026-2031)
Figure 85. Global Spinal Muscular Atrophy Medicine Sales Market ShareForecast by Application (2026-2031)
Figure 86. Global Spinal Muscular Atrophy Medicine Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global 2-phase Hybrid Stepper Motors Market Growth 2024-2030
US$ 3,660.00
December 2024
115 pages
Global Automobile Electronic Horn Market Growth 2024-2030
US$ 3,660.00
May 2024
117 pages
Global Laser Cutters Market Growth 2025-2031
US$ 3,660.00
October 2025
178 pages
Global Air-Cooled Generators Market Growth 2024-2030
US$ 3,660.00
May 2024
116 pages
Global Automatic Shrimp Peeler Market Growth 2024-2030
US$ 3,660.00
June 2024
111 pages
